| Popis: |
Ritu Rathi,1 Nitin Martandrao Mehetre,1 Shuchi Goyal,1 Inderbir Singh,1 Kampanart Huanbutta,2 Tanikan Sangnim3 1Chitkara College of Pharmacy, Chitkara University, Patiala, PB, India; 2Department of Manufacturing Pharmacy, College of Pharmacy, Rangsit University, Pathum Thani, Thailand; 3Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, ThailandCorrespondence: Tanikan Sangnim, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Burapha University, 169, Seansook, Muang, Chonburi, 20131, Thailand, Email tanikan@go.buu.ac.thAbstract: Multidisciplinary research has been conducted on novel drug delivery technologies to maximize therapeutic advantages while curtailing undesirable reactions. Drugs under BCS Class II often have a low bioavailability because the dissolution phase limits the absorption efficiency. In this review, risperidone was used as a pharmacological model to examine the impact of solubility enhancement at the primary administration site for such pharmaceuticals. For tackling drug-related pertains like disease diagnostics, therapy, and prophylactic measures at the cellular or molecular levels, implementing nanocarriers in therapeutics has significant potential. The comprehensive pharmaceutical compositions of risperidone nano-microparticles that have been developed to alleviate psychosis are highlighted in the study, which also illustrates potential future developments in such domains.Keywords: nanoparticles, risperidone, psychosis, micro particulates, bioavailability |
